Annovis Bio, Inc. SEC filings ANVS

Annovis Bio, Inc. has 314 filings in SEC EDGAR's recent list, going back to Jan 15, 2010. Its latest annual report, Form 10-K, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, regulation fd disclosure). The company's fiscal year ends on December 31.

Annovis Bio, Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 15, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Jul 29, 2026 —
4 Insider transaction May 21, 2026 May 20, 2026
4 Insider transaction Apr 3, 2026 Apr 2, 2026
144 Notice of proposed sale Apr 2, 2026 —
4 Insider transaction Dec 8, 2025 Dec 8, 2025
4/A Ownership document Nov 25, 2025 Nov 24, 2025
4 Insider transaction Nov 25, 2025 Nov 24, 2025
4 Insider transaction Nov 21, 2025 Nov 21, 2025
4 Insider transaction Nov 18, 2025 Nov 14, 2025
4 Insider transaction Nov 12, 2025 Oct 28, 2025
4 Insider transaction Nov 12, 2025 Oct 28, 2025
4 Insider transaction Nov 12, 2025 Sep 10, 2025
4 Insider transaction Sep 3, 2025 Aug 29, 2025
4 Insider transaction Aug 20, 2025 Aug 19, 2025
4 Insider transaction Jun 18, 2025 Jun 16, 2025
4 Insider transaction Jun 16, 2025 Jun 13, 2025
4 Insider transaction Jun 11, 2025 Jun 10, 2025
4 Insider transaction Jun 5, 2025 Jun 4, 2025
4 Insider transaction Jun 2, 2025 May 29, 2025
3 Initial insider ownership May 16, 2025 May 9, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 12, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Feb 10, 2025 —
4 Insider transaction Jul 3, 2024 Nov 17, 2023
4 Insider transaction Jul 3, 2024 Nov 17, 2023
4 Insider transaction Jul 3, 2024 Nov 17, 2023
4 Insider transaction Jul 3, 2024 Nov 17, 2023
4 Insider transaction Jul 3, 2024 Nov 17, 2023
SC 13G/A Amended ownership over 5% (passive) Nov 28, 2023 —
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4/A Ownership document Nov 22, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
4 Insider transaction Nov 21, 2023 Nov 20, 2023
SC 13G Ownership over 5% (passive) Nov 8, 2023 —
4 Insider transaction Apr 26, 2023 Apr 24, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Apr 11, 2023 Apr 7, 2023
4 Insider transaction Feb 8, 2023 Feb 6, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Jan 20, 2023 Jan 18, 2023
4 Insider transaction Aug 31, 2022 Aug 29, 2022
3 Initial insider ownership Aug 31, 2022 Aug 29, 2022
4 Insider transaction Jan 18, 2022 Jan 14, 2022
5 Annual insider ownership Jan 18, 2022 Dec 31, 2021
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Jan 5, 2022 Jan 3, 2022
4 Insider transaction Dec 8, 2021 Dec 6, 2021
4 Insider transaction Dec 8, 2021 Dec 6, 2021
4 Insider transaction Oct 13, 2021 Oct 11, 2021
4 Insider transaction Oct 13, 2021 Oct 12, 2021
4 Insider transaction Oct 13, 2021 Oct 11, 2021
4 Insider transaction Aug 23, 2021 Aug 19, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
4 Insider transaction Jul 9, 2021 Jul 7, 2021
3 Initial insider ownership Apr 19, 2021 Apr 9, 2021
SC 13G/A Amended ownership over 5% (passive) Jan 28, 2021 —
SC 13G Ownership over 5% (passive) Jul 21, 2020 —
SC 13G/A Amended ownership over 5% (passive) Jul 10, 2020 —
4 Insider transaction Jul 6, 2020 Jul 1, 2020
4 Insider transaction Jul 6, 2020 Jul 1, 2020
4 Insider transaction Jul 6, 2020 Jul 1, 2020
4/A Filing Jul 6, 2020 Jul 1, 2020
SC 13D Ownership over 5% (active) Apr 20, 2020 —
4 Insider transaction Apr 13, 2020 Apr 9, 2020
4 Insider transaction Apr 13, 2020 Apr 9, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
4 Insider transaction Feb 5, 2020 Jan 31, 2020
SC 13G Ownership over 5% (passive) Jan 30, 2020 —
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020
3 Initial insider ownership Jan 29, 2020 Jan 28, 2020

Showing 103 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANVS (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Malvern, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1477845
Former names
QR Pharma, Inc. (until Mar 15, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.